Pembrolizumab for Treatment of a Patient with Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa: JAMA Dermatology

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)708-710
Number of pages3
JournalJAMA Dermatol.
Volume156
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • alanine
  • bleomycin
  • glycine
  • levothyroxine sodium
  • pembrolizumab
  • CD274 protein, human
  • COL7A1 protein, human
  • collagen type 7
  • immunological antineoplastic agent
  • monoclonal antibody
  • programmed death 1 ligand 1
  • thyroxine
  • adult
  • arm amputation
  • autoimmune thyroiditis
  • cancer recurrence
  • cancer surgery
  • case report
  • clinical article
  • COL7A1 gene
  • drug response
  • electrochemotherapy
  • epidermolysis bullosa dystrophica
  • female
  • follow up
  • gene
  • genetic variability
  • histopathology
  • human
  • human tissue
  • Letter
  • multiple cancer
  • priority journal
  • skin biopsy
  • squamous cell skin carcinoma
  • ulcer healing
  • genetics
  • immunology
  • mutation
  • pathology
  • skin
  • skin tumor
  • squamous cell carcinoma
  • thyroiditis
  • treatment outcome
  • Adult
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Carcinoma, Squamous Cell
  • Collagen Type VII
  • Epidermolysis Bullosa Dystrophica
  • Female
  • Humans
  • Mutation
  • Skin
  • Skin Neoplasms
  • Thyroiditis
  • Thyroxine
  • Treatment Outcome

Cite this